Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Castration-resistant Prostate Cancer
Interventions: DRUG: Bone modifying agent
Sponsor: Ottawa Hospital Research Institute